Shares of US clinical-stage biotech Biohaven (NYSE: BHVN) rose 9.6% to $21.74 yesterday, after it announced an agreement with ...

Elite businesses could turn a single investment into a retirement fortune. Find out why BN, BRK.A, and BRK.B stocks are my ...

GPIQ's flexible strategy and selective covered-call approach have enabled it to outperform peers. Read why I upgrade the fund ...

Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...

We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...

Imagine what we could do if we could take that time and replace it with a single login to a centralized, one stop shop system ...

Part 2a is designed to confirm the primary dose-of-interest with a target enrollment of approximately 30 patients at each of two dose levels: 400mg QD 5:2 and 300mg QD 5:2 (intermittent daily dosing ...

MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will present 10 scientific abstracts—including both oral and poster ...

No-code platforms are software solutions that allow anyone to build web and mobile apps, using visual interfaces and ...

The MM-II trial was carried out in partnership with Israel-based Moebius Medical and included 397 patients in the US, Europe, ...

One such example is Novo Nordisk (NYSE: NVO), the Denmark-based pharmaceutical leader whose shares are exchanging hands for ...

Veracode, a global leader in application risk management, today announced new capabilities to help organizations address ... at 13:05 New Patient-Reported Outcomes from UGN-102 Clinical Trials Show ...